Drug Trial Radar · NCT04939428
Study of MK-4482 for Prevention of Coronavirus Disease 2019 (COVID-19) in Adults (MK-4482-013)
Last checked: Nov 19, 2026Latest source record: Sep 26, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,441
Actual
Start
Aug 11, 2021
Primary completion
Nov 16, 2022
Study completion Nov 16, 2022
Sponsor
- Lead sponsor
- Merck Sharp & Dohme LLCMerck & Co. (MRK)
- Sponsor type
- Industry
- First posted
- Jun 25, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Prevention
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The purpose of the study is to assess if the study medication (molnupiravir, MK-4482) will prevent symptomatic coronavirus disease 2019 (COVID-19) in adults who live with someone with confirmed COVID-19 infection. This is a phase 3, multicenter, randomized, double-blind, placebo-controlled study; half of the study participants will receive molnupiravir twice daily by mouth and the other half will receive a placebo. The primary objectives of the study are to determine if molnupiravir prevents symptomatic COVID-19 disease and to evaluate its safety and tolerability. All participants who develop COVID-19 during the study are still eligible for any COVID-19 treatment recommended by their doctor.
Conditions
- Coronavirus Disease (COVID-19)
Interventions
MolnupiravirDrug
Four molnupiravir 200 mg capsules taken by mouth.
PlaceboDrug
Placebo capsule matched to molnupiravir 200 mg capsules taken by mouth.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Who Had Undetectable SARS-CoV-2 in Baseline Nasopharyngeal (NP) Swabs and Developed COVID-19 (Laboratory-Confirmed SARS-CoV-2 Infection With Symptoms) Through Day 14Time frame: Day 14
- Percentage of Participants With ≥1 Adverse EventTime frame: 29 days
- Percentage of Participants Discontinuing From Study Therapy Due to AETime frame: Up to 5 days
Locations
226 sites in 23 countries. Site status is shown where the registry gives one.
Cahaba Research, Inc. ( Site 2523)
Birmingham, Alabama
The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2484)
Mesa, Arizona
The Institute for Liver Health DBA Arizona Clinical Trials ( Site 2448)
Tucson, Arizona
Hope Clinical Research ( Site 2400)
Canoga Park, California
Carbon Health ( Site 2515)
Carlsbad, California
UCSF Fresno ( Site 2528)
Fresno, California
ASCADA Research, LLC ( Site 2516)
Fullerton, California
Marvel Clinical Research ( Site 2490)
Huntington Beach, California
National Research Institute ( Site 2452)
Los Angeles, California
Valley Clinical Trials Inc. ( Site 2406)
Northridge, California
Carbon Health ( Site 2514)
Oakland, California
University of California Davis ( Site 2497)
Sacramento, California
Millennium Clinical Trials ( Site 2468)
Simi Valley, California
Future Innovative Treatments, LLC ( Site 2471)
Colorado Springs, Colorado
Emerson Clinical Research Institute ( Site 2457)
Washington D.C., District of Columbia
Synergy Healthcare ( Site 2521)
Bradenton, Florida
Accel Research Sites-DeLand Clinical Research Unit ( Site 2535)
DeLand, Florida
Velocity Clinical Research, Hallandale Beach ( Site 2485)
Hallandale, Florida
Indago Research and Health Center Inc ( Site 2412)
Hialeah, Florida
Advanced Research For Health Improvement LLC ( Site 2436)
Immokalee, Florida
Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2508)
Miami, Florida
CDC Research Institute, LLC ( Site 2540)
Port Saint Lucie, Florida
Clinical Research Trials of Florida ( Site 2402)
Tampa, Florida
Clinical Site Partners, LLC d/b/a CSP Miami ( Site 2425)
Winter Park, Florida
Balanced Life Healthcare Solutions/SKYCRNG ( Site 2539)
Lawrenceville, Georgia
Chicago Clinical Research Institute Inc ( Site 2454)
Chicago, Illinois
Rush University Medical Center ( Site 2510)
Chicago, Illinois
Southern Clinical Research Associates ( Site 2542)
Metairie, Louisiana
MedPharmics, LLC ( Site 2443)
Metairie, Louisiana
Institute of Human Virology ( Site 2504)
Baltimore, Maryland
Centennial Medical Group ( Site 2435)
Elkridge, Maryland
Jadestone Clinical Research, LLC ( Site 2530)
Silver Spring, Maryland
Michigan Center of Medical Research ( Site 2445)
Farmington Hills, Michigan
Michigan Center of Medical Research ( Site 2525)
Lathrup Village, Michigan
Allina Health Infectious Diseases Research Clinic ( Site 2507)
Minneapolis, Minnesota
Prime Health and Wellness/SKYCRNG ( Site 2538)
Fayette, Mississippi
Quinn Healthcare/Skycrng ( Site 2537)
Ridgeland, Mississippi
University of Missouri Hospital ( Site 2486)
Columbia, Missouri
Mercury Street Medical Group PLLC ( Site 2476)
Butte, Montana
University of Nebraska Medical Center ( Site 2430)
Omaha, Nebraska
Showing 40 of 226 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.